Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
RAPT Therapeutics, Inc. - Common Stock
(NQ:
RAPT
)
0.8254
-0.0046 (-0.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about RAPT Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
RAPT Therapeutics Announces $150 Million Private Placement
Today 7:10 EST
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
Today 7:00 EST
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 12, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 09, 2024
From
Schall Law
Via
GlobeNewswire
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
Company maintains solid cash position of $141.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
March 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
Company maintains solid cash position of $158.9 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
February 13, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 27, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
Company maintains strong cash position of $184.8 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
November 01, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 18, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
Company maintains strong cash position of $205 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
Company maintains strong cash position of $231.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 29, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
March 14, 2023
Company maintains strong cash position of $249.1 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.